Syntax for Science   Report issue

For profit Phase 2 Phase 3
Founded: Palma de Mallorca Spain (2012)

Organization Overview

First Clinical Trial
2016
NCT03003364
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Syntax for Science, S.L

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Hypersensitivity (Phase 3)

Infertility (Phase 3)

Infertility, Female (Phase 3)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Neuroendocrine Tumors (Phase 2)

Peanut Hypersensitivity (Phase 2)

Prostatic Neoplasms (Phase 3)

Rectal Neoplasms (Phase 2)

Spinal Cord Injuries (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 17